Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 1 to 5 of 5 results for calcitriol

  1. Palopegteriparatide for treating chronic hypoparathyroidism [ID6380]

    In development [GID-TA11454] Expected publication date: 16 July 2025

  2. Osteoporosis (QS149)

    This quality standard covers managing osteoporosis in adults (aged 18 and over), including assessing risk and preventing fragility fractures. It describes high-quality care in priority areas for improvement.

  3. Psoriasis: assessment and management (CG153)

    This guideline covers assessing and managing psoriasis in adults, young people and children. It aims to improve long-term disease control and quality of life for people with psoriasis.

  4. Etelcalcetide for treating secondary hyperparathyroidism (TA448)

    Evidence-based recommendations on etelcalcetide (Parsabiv) for treating secondary hyperparathyroidism in adults with chronic kidney disease on haemodialysis.

  5. Chronic kidney disease: assessment and management (NG203)

    This guideline covers care and treatment for people with, or at risk of, chronic kidney disease (CKD). It aims to prevent or delay the progression, and reduce the risk of complications and cardiovascular disease. It also covers managing anaemia and hyperphosphataemia associated with CKD.